Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033

Table of Contents

1 Market

• 1.1 Global Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.2.1 Inclusion Criteria
    • 1.1.2.2 Exclusion Criteria
  • 1.1.3 Market Overview
    • 1.1.3.1 Market Footprint
    • 1.1.3.2 Market Size and Future Growth Potential
  • 1.1.4 COVID-19 Impact on the Market
    • 1.1.4.1 Impact on Research and Clinical Operations
    • 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
• 1.2 Industry Analysis
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Legal Requirements and Framework in the U.S.
    • 1.2.1.2 Legal Requirements and Framework in Europe
      • 1.2.1.2.1 U.K.
      • 1.2.1.2.2 Spain
    • 1.2.1.3 Legal Requirements and Framework in Asia-Pacific
      • 1.2.1.3.1 Japan
      • 1.2.1.3.2 China
      • 1.2.1.3.3 India
      • 1.2.1.3.4 Taiwan
  • 1.2.2 Patent Analysis
    • 1.2.2.1 Patent Filing Trend (by Country)
    • 1.2.2.2 Patent Filing Trend (by Year)
  • 1.2.3 Funding Scenario
• 1.3 Market Dynamics
  • 1.3.1 Overview
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    • 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    • 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  • 1.3.3 Market Challenges
    • 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    • 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    • 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    • 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Competitive Insights

• 2.1 Competitive Benchmarking
  • 2.1.1 Key Strategies and Developments
    • 2.1.1.1 Funding Activities
    • 2.1.1.2 New Offerings, Product Upgradation, and Approvals
    • 2.1.1.3 Mergers and Acquisitions
    • 2.1.1.4 Partnerships, Collaborations, And Business Expansion
  • 2.1.2 Market Share Analysis
    • 2.1.2.1 Rare Disease Genetic Testing Market, Market Share Analysis of Companies Offering Products
    • 2.1.2.2 Rare Disease Genetic Testing Market, Market Share Analysis of Companies Offering Services.
  • 2.1.3 Growth-Share Analysis
    • 2.1.3.1 By Disease Type
    • 2.1.3.2 By Technology Type

3 Global Rare Disease Genetic Testing Market (by disease type), 2022-2033

• 3.1 Overview
• 3.2 Gastroenterology Disease
• 3.3 Endocrine and Metabolism Disease
• 3.4 Cardiovascular Disease
• 3.5 Neurology Disease
• 3.6 Hematology and Oncology Disease
• 3.7 Dermatology Disease
• 3.8 Other Diseases

4 Global Rare Disease Genetic Testing Market (by Offering), 2022-2033

• 4.1 Overview
• 4.2 Products
• 4.3 Services

5 Global Rare Disease Genetic Testing Market (by Specialty Type), 2022-2033

• 5.1 Overview
• 5.2 Molecular Genetic Tests
• 5.3 Chromosomal Genetic Tests
• 5.4 Biochemical Genetic Tests

6 Global Rare Disease Genetic Testing Market (by Sample Type), 2022-2033

• 6.1 Overview
• 6.2 DNA Sample
• 6.3 Buccal Swab Sample
• 6.4 Blood Sample
• 6.5 Saliva Sample
• 6.6 Others

7 Global Rare Disease Genetic Testing Market (by Trait Type), 2022-2033

• 7.1 Overview
• 7.2 Inherited Trait
• 7.3 Acquired Trait

8 Global Rare Disease Genetic Testing Market (by Technology), 2022-2033

• 8.1 Overview
• 8.2 Polymerase Chain Reaction (PCR)
• 8.3 Next-Generation Sequencing (NGS)
  • 8.3.1 Whole Genome Sequencing
  • 8.3.2 Whole Exome Sequencing
• 8.4 Microarrays
• 8.5 Sanger Sequencing
• 8.6 Other Technologies

9 Global Rare Disease Genetic Testing Market (by Age Group), 2022-2033

• 9.1 Overview
• 9.2 Prenatal
• 9.3 Neonate and Infant
• 9.4 Children and Adolescent
• 9.5 Adult

10 Global Rare Disease Genetic Testing Market (by End User), 2022-2033

• 10.1 Overview
• 10.2 Hospitals
• 10.3 Diagnostic Laboratories
• 10.4 Other End User

11 Global Rare Disease Genetic Testing Market (by Region)

• 11.1 North America Rare Disease Genetic Testing Market
  • 11.1.1 Market Dynamics
    • 11.1.1.1 Impact Analysis
  • 11.1.2 Market Sizing and Forecast
    • 11.1.2.1 North America Rare Disease Genetic Testing Market (by Disease Type)
    • 11.1.2.2 North America Rare Disease Genetic Testing Market (by Technology)
    • 11.1.2.3 North America Rare Disease Genetic Testing Market (by Country)
      • 11.1.2.3.1 U.S.
        • 11.1.2.3.1.1 Market Dynamics
        • 11.1.2.3.1.2 Market Size and Forecast
        • 11.1.2.3.1.2.1 U.S. Rare Disease Genetic Testing Market (by Disease Type)
        • 11.1.2.3.1.2.2 U.S. Rare Disease Genetic Testing Market (by Technology)
      • 11.1.2.3.2 Canada
        • 11.1.2.3.2.1 Market Dynamics
        • 11.1.2.3.2.2 Market Size and Forecast
        • 11.1.2.3.2.2.1 Canada Rare Disease Genetic Testing Market (by Disease Type)
        • 11.1.2.3.2.2.2 Canada Rare Disease Genetic Testing Market (by Technology)
• 11.2 Europe Rare Disease Genetic Testing Market
  • 11.2.1 Market Dynamics
    • 11.2.1.1 Impact Analysis
  • 11.2.2 Market Sizing and Forecast
    • 11.2.2.1 Europe Rare Disease Genetic Testing Market (by Disease Type)
    • 11.2.2.2 Europe Rare Disease Genetic Testing Market (by Technology)
    • 11.2.2.3 Europe Rare Disease Genetic Testing Market (by Country)
      • 11.2.2.3.1 Germany
        • 11.2.2.3.1.1 Market Dynamics
        • 11.2.2.3.1.2 Market Size and Forecast
        • 11.2.2.3.1.2.1 Germany Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.1.2.2 Germany Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.2 U.K.
        • 11.2.2.3.2.1 Market Dynamics
        • 11.2.2.3.2.2 Market Size and Forecast
        • 11.2.2.3.2.2.1 U.K Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.2.2.2 U.K. Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.3 France
        • 11.2.2.3.3.1 Market Dynamics
        • 11.2.2.3.3.2 Market Size and Forecast
        • 11.2.2.3.3.2.1 France Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.3.2.2 France Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.4 Italy
        • 11.2.2.3.4.1 Market Dynamics
        • 11.2.2.3.4.2 Market Size and Forecast
        • 11.2.2.3.4.2.1 Italy Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.4.2.2 Italy Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.5 Spain
        • 11.2.2.3.5.1 Market Dynamics
        • 11.2.2.3.5.2 Market Size and Forecast
        • 11.2.2.3.5.2.1 Spain Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.5.2.2 Spain Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.6 Russia
        • 11.2.2.3.6.1 Market Dynamics
        • 11.2.2.3.6.2 Market Size and Forecast
        • 11.2.2.3.6.2.1 Russia Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.6.2.2 Russia Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.7 Rest-of-Europe
        • 11.2.2.3.7.1 Market Dynamics
        • 11.2.2.3.7.2 Market Size and Forecast
        • 11.2.2.3.7.2.1 Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.7.2.2 Rest-of-Europe Rare Disease Genetic Testing Market (by Technology)
• 11.3 Asia-Pacific Rare Disease Genetic Testing Market
  • 11.3.1 Market Dynamics
    • 11.3.1.1 Impact Analysis
  • 11.3.2 Market Size and Forecast
    • 11.3.2.1 Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
    • 11.3.2.2 Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
    • 11.3.2.3 Asia-Pacific Rare Disease Genetic Testing Market (by Country)
      • 11.3.2.3.1 Japan
        • 11.3.2.3.1.1 Market Dynamics
        • 11.3.2.3.1.2 Market Size and Forecast
        • 11.3.2.3.1.2.1 Japan Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.1.2.2 Japan Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.2 China
        • 11.3.2.3.2.1 Market Dynamics
        • 11.3.2.3.2.2 Market Size and Forecast
        • 11.3.2.3.2.2.1 China Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.2.2.2 China Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.3 Australia
        • 11.3.2.3.3.1 Market Dynamics
        • 11.3.2.3.3.2 Market Size and Forecast
        • 11.3.2.3.3.2.1 Australia Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.3.2.2 Australia Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.4 South Korea
        • 11.3.2.3.4.1 Market Dynamics
        • 11.3.2.3.4.2 Market Size and Forecast
        • 11.3.2.3.4.2.1 South Korea Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.4.2.2 South Korea Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.5 India
        • 11.3.2.3.5.1 Market Dynamics
        • 11.3.2.3.5.2 Market Size and Forecast
        • 11.3.2.3.5.2.1 India Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.5.2.2 India Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.6 Singapore
        • 11.3.2.3.6.1 Market Dynamics
        • 11.3.2.3.6.2 Market Size and Forecast
        • 11.3.2.3.6.2.1 Singapore Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.6.2.2 Singapore Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.7 Rest-of-Asia-Pacific
        • 11.3.2.3.7.1 Market Dynamics
        • 11.3.2.3.7.2 Market Size and Forecast
        • 11.3.2.3.7.2.1 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.7.2.2 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
• 11.4 Latin America Rare Disease Genetic Testing Market
  • 11.4.1 Market Dynamics
    • 11.4.1.1 Impact Analysis
  • 11.4.2 Market Size and Forecast
    • 11.4.2.1 Latin America Rare Disease Genetic Testing Market (by Disease Type)
    • 11.4.2.2 Latin America Rare Disease Genetic Testing Market (by Technology)
    • 11.4.2.3 Latin America Rare Disease Genetic Testing Market (by Country)
      • 11.4.2.3.1 Brazil
        • 11.4.2.3.1.1 Market Dynamics
        • 11.4.2.3.1.2 Market Size and Forecast
        • 11.4.2.3.1.2.1 Brazil Rare Disease Genetic Testing Market (by Disease Type)
        • 11.4.2.3.1.2.2 Brazil Rare Disease Genetic Testing Market (by Technology)
      • 11.4.2.3.2 Mexico
        • 11.4.2.3.2.1 Market Dynamics
        • 11.4.2.3.2.2 Market Size and Forecast
        • 11.4.2.3.2.2.1 Mexico Rare Disease Genetic Testing Market (by Disease Type)
        • 11.4.2.3.2.2.2 Mexico Rare Disease Genetic Testing Market (by Technology)
      • 11.4.2.3.3 Rest-of-Latin America
        • 11.4.2.3.3.1 Market Dynamics
        • 11.4.2.3.3.2 Market Size and Forecast
        • 11.4.2.3.3.2.1 Rest-of-Latin America Rare Disease Genetic Testing Market (by Disease Type)
        • 11.4.2.3.3.2.2 Rest-of-Latin America Rare Disease Genetic Testing Market (by Technology)
• 11.5 Rest-of-the-World Rare Disease Genetic Testing Market
  • 11.5.1 Market Dynamics
    • 11.5.1.1 Impact Analysis
  • 11.5.2 Market Size and Forecast
    • 11.5.2.1 Rest-of-the-World Rare Disease Genetic Testing Market (by Disease Type)
    • 11.5.2.2 Rest-of-the-World Rare Disease Genetic Testing Market (by Technology)

12 Company Profiles

• 12.1 Overview
  • 12.1.1 23andMe Holding Co.
    • 12.1.1.1 Company Overview
    • 12.1.1.2 Role of 23andMe Holding Co. in the Global Rare Disease Genetic Testing Market
    • 12.1.1.3 Financials
    • 12.1.1.4 Recent Developments
    • 12.1.1.5 Analyst Perspective
  • 12.1.2 3billion, Inc.
    • 12.1.2.1 Company Overview
    • 12.1.2.2 Role of 3billion, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.2.3 Recent Developments
    • 12.1.2.4 Analyst Perspective
  • 12.1.3 Agilent Technologies, Inc.
    • 12.1.3.1 Company Overview
    • 12.1.3.2 Role of Agilent Technologies, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.3.3 Financials
    • 12.1.3.4 Recent Developments
    • 12.1.3.5 Analyst Perspective
  • 12.1.4 Konica Minolta (Ambry Genetics, Inc.)
    • 12.1.4.1 Company Overview
    • 12.1.4.2 Role of Konica Minolta (Ambry Genetics, Inc.) in the Global Rare Disease Genetic Testing Market
    • 12.1.4.3 Financials
    • 12.1.4.4 Recent Developments
    • 12.1.4.5 Analyst Perspective
  • 12.1.5 BGI Group
    • 12.1.5.1 Company Overview
    • 12.1.5.2 Role of BGI Group in the Global Rare Disease Genetic Testing Market
    • 12.1.5.3 Financials
    • 12.1.5.4 Recent Developments
    • 12.1.5.5 Analyst Perspective
  • 12.1.6 CENTOGENE N.V.
    • 12.1.6.1 Company Overview
    • 12.1.6.2 Role of CENTOGENE N.V. in the Global Rare Disease Genetic Testing Market
    • 12.1.6.3 Financials
    • 12.1.6.4 Recent Developments
    • 12.1.6.5 Analyst Perspective
  • 12.1.7 Eurofins Scientific SE
    • 12.1.7.1 Company Overview
    • 12.1.7.2 Role of Eurofins Scientific SE in the Global Rare Disease Genetic Testing Market
    • 12.1.7.3 Financials
    • 12.1.7.4 Recent Developments
    • 12.1.7.5 Analyst Perspective
  • 12.1.8 GeneDx, Holdings Corp.
    • 12.1.8.1 Company Overview
    • 12.1.8.2 Role of GeneDx, Holdings Corp. in the Global Rare Disease Genetic Testing Market
    • 12.1.8.3 Financials
    • 12.1.8.4 Recent Developments
    • 12.1.8.5 Analyst Perspective
  • 12.1.9 Azenta U.S., Inc. (GENEWIZ, Inc.)
    • 12.1.9.1 Company Overview
    • 12.1.9.2 Role of Azenta U.S., Inc. (GENEWIZ, Inc.) in the Global Rare Disease Genetic Testing Market
    • 12.1.9.3 Financials
    • 12.1.9.4 Recent Developments
    • 12.1.9.5 Analyst Perspective
  • 12.1.10 Illumina, Inc.
    • 12.1.10.1 Company Overview
    • 12.1.10.2 Role of Illumina, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.10.3 Financials
    • 12.1.10.4 Recent Developments
    • 12.1.10.5 Analyst Perspective
  • 12.1.11 Invitae Corporation
    • 12.1.11.1 Company Overview
    • 12.1.11.2 Role of Invitae Corporation in the Global Rare Disease Genetic Testing Market
    • 12.1.11.3 Financials
    • 12.1.11.4 Recent Developments
    • 12.1.11.5 Analyst Perspective
  • 12.1.12 Laboratory Corporation of America Holdings
    • 12.1.12.1 Company Overview
    • 12.1.12.2 Role of Laboratory Corporation of America Holdings in the Global Rare Disease Genetic Testing Market
    • 12.1.12.3 Financials
    • 12.1.12.4 Recent Developments
    • 12.1.12.5 Analyst Perspective
  • 12.1.13 Medgenome
    • 12.1.13.1 Company Overview
    • 12.1.13.2 Role of Medgenome in the Global Rare Disease Genetic Testing Market
    • 12.1.13.3 Recent Developments
    • 12.1.13.4 Analyst Perspective
  • 12.1.14 Myriad Genetics, Inc.
    • 12.1.14.1 Company Overview
    • 12.1.14.2 Role of Myriad Genetics, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.14.3 Financials
    • 12.1.14.4 Recent Developments
    • 12.1.14.5 Analyst Perspective
  • 12.1.15 OPKO Health, Inc.
    • 12.1.15.1 Company Overview
    • 12.1.15.2 Role of OPKO Health, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.15.3 Financials
    • 12.1.15.4 Recent Developments
    • 12.1.15.5 Analyst Perspective
  • 12.1.16 PerkinElmer, Inc.
    • 12.1.16.1 Company Overview
    • 12.1.16.2 Role of PerkinElmer, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.16.3 Financials
    • 12.1.16.4 Key Insights about the Financial Health of the Company
    • 12.1.16.5 Recent Developments
    • 12.1.16.6 Analyst Perspective
  • 12.1.17 Exact Sciences Corporation (Prevention Genetics)
    • 12.1.17.1 Company Overview
    • 12.1.17.2 Role of Exact Sciences Corporation (Prevention Genetics) in the Global Rare Disease Genetic Testing Market
    • 12.1.17.3 Financials
    • 12.1.17.4 Recent Developments
    • 12.1.17.5 Analyst Perspective
  • 12.1.18 QIAGEN N.V.
    • 12.1.18.1 Company Overview
    • 12.1.18.2 Role of QIAGEN N.V. in the Global Rare Disease Genetic Testing Market
    • 12.1.18.3 Financials
    • 12.1.18.4 Recent Developments
    • 12.1.18.5 Analyst Perspective
  • 12.1.19 Quest Diagnostics Incorporated
    • 12.1.19.1 Company Overview
    • 12.1.19.2 Role of Quest Diagnostics Incorporated in the Global Rare Disease Genetic Testing Market
    • 12.1.19.3 Financials
    • 12.1.19.4 Analyst Perspective
  • 12.1.20 Strand Life Science Pvt Ltd.
    • 12.1.20.1 Company Overview
    • 12.1.20.2 Role of Strand Life Science Pvt Ltd. in the Global Rare Disease Genetic Testing Market
    • 12.1.20.3 Recent Developments
    • 12.1.20.4 Analyst Perspective

List of Figures

• Figure 1: Global Prevalence Rare Disease, 2022
• Figure 2: Global Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 3: Global Rare Disease Genetic Testing Market, Market Dynamics
• Figure 4: Most Frequently Studied Rare Diseases, 2021
• Figure 5: Global Rare Disease Genetic Testing Market Share (by Technology), 2022 and 2033
• Figure 6: Global Rare Disease Genetic Testing Market Share (by Specialty Type), 2022 and 2033
• Figure 7: Global Rare Disease Genetic Testing Market Share (by Offering), 2022 and 2033
• Figure 8: Global Rare Disease Genetic Testing Market Share (by Disease Type), 2022 and 2033
• Figure 9: Global Rare Disease Genetic Testing Market Share (by Sample Type), 2022 and 2033
• Figure 10: Global Rare Disease Genetic Testing Market Share (by Trait Type), 2022 and 2033
• Figure 11: Global Rare Disease Genetic Testing Market Share (by End User), 2022 and 2033
• Figure 12: Global Rare Disease Genetic Testing Market (by Region), $Billion, 2022 and 2033
• Figure 13: Share of Key Developments and Strategies, January 2019-June 2023
• Figure 14: Global Rare Disease Genetic Testing Market Segmentation
• Figure 15: Global Rare Disease Genetic Testing Market: Research Methodology
• Figure 16: Primary Research Methodology
• Figure 17: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 18: Top-Down Approach (Segment-Wise Analysis)
• Figure 19: Global Rare Disease Genetic Testing Market Potential, $Billion, 2022-2033
• Figure 20: Regulatory Scenario in Europe (by Country)
• Figure 21: Global Rare Disease Genetic Testing Market, Patent Analysis (by Country), January 2018- June 2023
• Figure 22: Global Rare Disease Genetic Testing Market, Patent Analysis (by Year), January 2018-June 2023
• Figure 23: NIH Funding on Rare Diseases, $Million, 2013-2023
• Figure 24: Global Rare Disease Genetic Testing Market Dynamics
• Figure 25: Rare Disease Prevalence in India, 2022
• Figure 26: Global Prevalence of Rare Diseases, 2022
• Figure 27: Most Frequently Studied Rare Diseases, 2021
• Figure 28: Publications Related to the Use of Artificial Intelligence for Rare Disease Diagnosis, 2015-2022
• Figure 29: Global Rare Disease Genetic Testing Market, Number of Key Developments and Strategies, January 2019-June 2023
• Figure 30: Global Rare Disease Genetic Testing Market, Number of Funding Activities, January 2019-June 2023
• Figure 31: Global Rare Disease Genetic Testing Market, Number of New Offerings, Product Upgradation, and Approvals January 2019-June 2023
• Figure 32: Global Rare Disease Genetic Testing Market, Number of Mergers and Acquisitions, January 2019-June 2023
• Figure 33: Global Rare Disease Genetic Testing Market, Number of Partnerships, Collaborations, and Business Expansions, January 2019-June 2023
• Figure 34: Global Rare Disease Genetic Testing Market, Company Revenue Share Analysis of Companies Offering Products, $Billion, 2022
• Figure 35: Global Rare Disease Genetic Testing Market, Company Revenue Share Analysis of Companies Offering Services, $Billion, 2022
• Figure 36: Global Rare Disease Genetic Testing Market, Growth-Share Matrix (by Disease Type), 2023-2033
• Figure 37: Global Rare Disease Genetic Testing Market, Growth-Share Matrix (by Technology Type), 2023-2033
• Figure 38: Global Rare Disease Genetic Testing Market (by Disease Type)
• Figure 39: Global Rare Disease Genetic Testing Market (by Disease Type), $Billion, 2022-2032
• Figure 40: Global Rare Disease Genetic Testing Market (Gastroenterology Disease), $Billion, 2022-2033
• Figure 41: Global Rare Disease Genetic Testing Market (Endocrine and Metabolism Disease), $Billion, 2022-2033
• Figure 42: Global Rare Disease Genetic Testing Market (Cardiovascular Disease), $Billion, 2022-2033
• Figure 43: Global Rare Disease Genetic Testing Market (Neurology Disease), $Billion, 2022-2033
• Figure 44: Global Rare Disease Genetic Testing Market (Hematology and Oncology Disease), $Billion, 2022-2033
• Figure 45: Global Rare Disease Genetic Testing Market (Dermatology Disease), $Billion, 2022-2033
• Figure 46: Global Rare Disease Genetic Testing Market (Other Diseases), $Billion, 2022-2033
• Figure 47: Global Rare Disease Genetic Testing Market (by Offering)
• Figure 48: Global Rare Disease Genetic Testing Market (by Offering), $Billion, 2022-2032
• Figure 49: Global Rare Disease Genetic Testing Market (Products), $Billion, 2022-2033
• Figure 50: Global Rare Disease Genetic Testing Market (Services), $Billion, 2022-2033
• Figure 51: Global Rare Disease Genetic Testing Market (by Specialty Type)
• Figure 52: Global Rare Disease Genetic Testing Market (by Specialty Type), $Billion, 2022-2032
• Figure 53: Global Rare Disease Genetic Testing Market (Molecular Genetic Tests), $Billion, 2022-2033
• Figure 54: Global Rare Disease Genetic Testing Market (Chromosomal Genetic Tests), $Billion, 2022-2033
• Figure 55: Global Rare Disease Genetic Testing Market (Biochemical Genetic Tests), $Billion, 2022-2033
• Figure 56: Global Rare Disease Genetic Testing Market (by Sample Type)
• Figure 57: Global Rare Disease Genetic Testing Market (by Sample Type), $Billion, 2022-2032
• Figure 58: Global Rare Disease Genetic Testing Market (DNA Sample), $Billion, 2022-2033
• Figure 59: Global Rare Disease Genetic Testing Market (Buccal Swab Sample), $Billion, 2022-2033
• Figure 60: Global Rare Disease Genetic Testing Market (Blood Sample), $Billion, 2022-2033
• Figure 61: Global Rare Disease Genetic Testing Market (Saliva Sample), $Billion, 2022-2033
• Figure 62: Global Rare Disease Genetic Testing Market (Others), $Billion, 2022-2033
• Figure 63: Global Rare Disease Genetic Testing Market (by Trait Type)
• Figure 64: Global Rare Disease Genetic Testing Market (by Trait Type), $Billion, 2022-2032
• Figure 65: Global Rare Disease Genetic Testing Market (Inherited Trait), $Billion, 2022-2033
• Figure 66: Global Rare Disease Genetic Testing Market (Acquired Trait), $Billion, 2022-2033
• Figure 67: Global Rare Disease Genetic Testing Market (by Technology)
• Figure 68: Global Rare Disease Genetic Testing Market (by Technology), $Billion, 2022-2032
• Figure 69: Global Rare Disease Genetic Testing Market (Polymerase Chain Reaction (PCR)), $Billion, 2022-2033
• Figure 70: Global Rare Disease Genetic Testing Market (by Next-Generation Sequencing (NGS)), $Billion, 2022-2033
• Figure 71: Global Rare Disease Genetic Testing Market (Whole Genome Sequencing), $Billion, 2022-2033
• Figure 72: Global Rare Disease Genetic Testing Market (Whole Exome Sequencing), $Billion, 2022-2033
• Figure 73: Global Rare Disease Genetic Testing Market (Microarrays), $Billion, 2022-2033
• Figure 74: Global Rare Disease Genetic Testing Market (Sanger Sequencing), $Billion, 2022-2033
• Figure 75: Global Rare Disease Genetic Testing Market (Other Technologies), $Billion, 2022-2033
• Figure 76: Global Rare Disease Genetic Testing Market (by Age Group)
• Figure 77: Global Rare Disease Genetic Testing Market (by Age Group), $Billion, 2022-2032
• Figure 78: Global Rare Disease Genetic Testing Market (Prenatal), $Billion, 2022-2033
• Figure 79: Global Rare Disease Genetic Testing Market (Neonate and Infant), $Billion, 2022-2033
• Figure 80: Global Rare Disease Genetic Testing Market (Children and Adolescent), $Billion, 2022-2033
• Figure 81: Global Rare Disease Genetic Testing Market (Adult), $Billion, 2022-2033
• Figure 82: Global Rare Disease Genetic Testing Market (by End User)
• Figure 83: Global Rare Disease Genetic Testing Market (by End User), $Billion, 2022-2032
• Figure 84: Global Rare Disease Genetic Testing Market (Hospitals), $Billion, 2022-2033
• Figure 85: Global Rare Disease Genetic Testing Market (Diagnostic Laboratories), $Billion, 2022-2033
• Figure 86: Global Rare Disease Genetic Testing Market (Other End User), $Billion, 2022-2033
• Figure 87: Global Rare Disease Genetic Testing Market Share (by Region), 2022-2033
• Figure 88: North America Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 89: North America Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 90: North America Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 91: North America Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
• Figure 92: U.S. Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 93: U.S. Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 94: U.S. Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 95: Canada Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 96: Canada Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 97: Canada Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 98: Europe Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 99: Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 100: Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 101: Europe Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
• Figure 102: Germany Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 103: Germany Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 104: Germany Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 105: U.K. Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 106: U.K. Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 107: U.K. Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 108: France Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 109: France Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 110: France Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 111: Italy Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 112: Italy Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 113: Italy Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 114: Spain Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 115: Spain Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 116: Spain Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 117: Russia Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 118: Russia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 119: Russia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 120: Rest-of-Europe Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 121: Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 122: Rest-of-Europe Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 123: Asia-Pacific Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 124: Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 125: Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 126: Asia-Pacific Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
• Figure 127: Japan Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 128: Japan Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 129: Japan Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 130: China Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 131: China Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 132: China Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 133: Australia Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 134: Australia Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 135: Australia Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 136: South Korea Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 137: South Korea Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 138: South Korea Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 139: India Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 140: India Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 141: India Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 142: Singapore Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 143: Singapore Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 144: Singapore Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 145: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 146: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 147: Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 148: Latin America Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 149: Latin America Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 150: Latin America Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 151: Latin America Rare Disease Genetic Testing Market (by Country), % Share, 2022 and 2033
• Figure 152: Brazil Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 153: Brazil Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 154: Brazil Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 155: Mexico Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 156: Mexico Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 157: Mexico Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 158: Rest-of-Latin America Rare Disease Genetic Testing Market, $Million, 2022-2033
• Figure 159: Rest-of-Latin America Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 160: Rest-of-Latin America Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 161: Rest-of-the-World Rare Disease Genetic Testing Market, $Billion, 2022-2033
• Figure 162: Rest-of-the-World Rare Disease Genetic Testing Market (by Disease Type), $Million, 2022-2033
• Figure 163: Rest-of-the-World Rare Disease Genetic Testing Market (by Technology), $Million, 2022-2033
• Figure 164: Global Rare Disease Genetic Testing Market, Total Number of Key Companies Profiled
• Figure 165: 23andMe, Inc: Product Portfolio
• Figure 166: 23andMe Holding Co.: Overall Financials, $Million, 2020-2022
• Figure 167: 23andMe Holding Co.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 168: 23andMe Holding Co.: Net Revenue (by Region), $Million, 2020-2022
• Figure 169: 23andMe Holding Co.: R&D Expenditure, $Million, 2020-2022
• Figure 170: 3billion, Inc: Product Portfolio
• Figure 171: Agilent Technologies, Inc: Product Portfolio
• Figure 172: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
• Figure 173: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 174: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
• Figure 175: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 176: Konica Minolta (Ambry Genetics, Inc.): Product Portfolio
• Figure 177: Konica Minolta (Ambry Genetics, Inc.).: Overall Financials, $Million, 2020-2022
• Figure 178: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Segment), $Million, 2020-2022
• Figure 179: Konica Minolta (Ambry Genetics, Inc.): Net Revenue (by Region), $Million, 2020-2022
• Figure 180: Konica Minolta (Ambry Genetics, Inc.): R&D Expenditure, $Million, 2020-2022
• Figure 181: BGI Genomics: Product Portfolio
• Figure 182: BGI Genomics.: Overall Financials, $Million, 2020-2022
• Figure 183: CENTOGENE N.V.: Product Portfolio
• Figure 184: CENTOGENE N.V.: Overall Financials, $Million, 2020-2022
• Figure 185: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 186: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2020-2022
• Figure 187: CENTOGENE N.V.: R&D Expenditure, $Million, 2020-202
• Figure 188: Eurofins Scientific SE: Product Portfolio
• Figure 189: Eurofins Scientific SE: Overall Financials, $Million, 2020-2022
• Figure 190: Eurofins Scientific SE: Net Revenue (by Segment), $Million, 2020-2022
• Figure 191: Eurofins Scientific SE: Net Revenue (by Region), $Million, 2020-2022
• Figure 192: GeneDx, Holdings Corp.: Product Portfolio
• Figure 193: GeneDx, Holdings Corp.: Overall Financials, $Million, 2020-2022
• Figure 194: GeneDx, Holdings Corp.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 195: GeneDx, Holdings Corp.: R&D Expenditure, $Million, 2020-2022
• Figure 196: Azenta U.S., Inc. (GENEWIZ, Inc.): Product Portfolio
• Figure 197: Azenta U.S., Inc. (GENEWIZ, Inc.): Overall Financials, $Million, 2020-2022
• Figure 198: Azenta U.S., Inc. (GENEWIZ, Inc.): Net Revenue (by Segment), $Million, 2020-2022
• Figure 199: Azenta U.S., Inc. (GENEWIZ, Inc.): Net Revenue (by Region), $Million, 2020-2022
• Figure 200: Illumina, Inc.: Product Portfolio
• Figure 201: Illumina, Inc.: Overall Financials, $Million, 2020-2022
• Figure 202: Illumina, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 203: Illumina, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 204: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 205: Invitae Corporation: Product Portfolio
• Figure 206: Invitae Corporation: Overall Financials, $Million, 2020-2022
• Figure 207: Invitae Corporation: Net Revenue (by Segment), $Million, 2020-2022
• Figure 208: Invitae Corporation: Net Revenue (by Region), $Million, 2020-2022
• Figure 209: Laboratory Corporation of America Holdings: Product Portfolio
• Figure 210: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2020-2022
• Figure 211: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2020-2022
• Figure 212: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2020-2022
• Figure 213: Medgenome: Product Portfolio
• Figure 214: Myriad Genetics, Inc.: Product Portfolio
• Figure 215: Myriad Genetics, Inc.: Overall Financials, $Million, 2020-2022
• Figure 216: Myriad Genetics, Inc.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 217: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 218: OPKO Health, Inc.: Product Portfolio
• Figure 219: OPKO Health, Inc.: Overall Financials, $Million, 2020-2022
• Figure 220: OPKO Health, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 221: PerkinElmer, Inc.: Product Portfolio
• Figure 222: PerkinElmer, Inc.: Overall Financials, $Million, 2020-2022
• Figure 223: PerkinElmer, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 224: PerkinElmer, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 225: PerkinElmer, Inc.: R&D Expenditure, $Million, 2020-2022
• Figure 226: Exact Sciences Corporation (Prevention Genetics): Product Portfolio
• Figure 227: Exact Sciences Corporation: Overall Financials, $Million, 2020-2022
• Figure 228: Exact Sciences Corporation: Revenue (by Segment), $Million, 2020-2022
• Figure 229: Exact Sciences Corporation: Revenue (by Region), $Million, 2020-2022
• Figure 230: Exact Sciences Corporation: R&D Expenditure, $Million, 2020-2022
• Figure 231: QIAGEN N.V.: Product Portfolio
• Figure 232: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
• Figure 233: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
• Figure 234: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
• Figure 235: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
• Figure 236: Quest Diagnostics Incorporated.: Product Portfolio
• Figure 237: Quest Diagnostics Incorporated: Overall Financials, $Million, 2020-2022
• Figure 238: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2020-2022
• Figure 239: Strand Life Science Pvt Ltd.: Product Portfolio

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Funding for Rare Disease Research
• Table 3: Technological Advancements in the Rare Disease Genetic Testing Ecosystem
• Table 4: Expansion of Medicare Coverage for Rare Disease Genetic Testing Tests (by Companies)
• Table 5: North America Rare Disease Genetic Testing Market, Impact Analysis
• Table 6: Europe Rare Disease Genetic Testing Market, Impact Analysis
• Table 7: Asia-Pacific Rare Disease Genetic Testing Market, Impact Analysis
• Table 8: Latin America Rare Disease Genetic Testing Market, Impact Analysis
• Table 9: Rest-of-the-World Rare Disease Genetic Testing Market, Impact Analysis